Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals

Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals

Peptide receptor radionuclide therapy (PRRT) using Lutetium-177 (<sup>177</sup>Lu) based radiopharmaceuticals has emerged as a therapeutic area in the field of nuclear medicine and oncology, allowing for personalized medicine. Since the first market authorization in 2018 of [¹⁷⁷Lu]Lu-DOT...

Full description

Bibliographic Details
Main Authors:	Typhanie Ladrière, Julie Faudemer, Elise Levigoureux, Damien Peyronnet, Cédric Desmonts, Jonathan Vigne
Format:	Article
Language:	English
Published:	MDPI AG 2023-04-01
Series:	Pharmaceutics
Subjects:	radiopharmaceuticals Lutetium-177 nuclear medicine peptide receptor radionuclide therapy safety dosimetry
Online Access:	https://www.mdpi.com/1999-4923/15/4/1240

Similar Items

Activity quantification and dosimetry in radiopharmaceutical therapy with reference to 177Lutetium
by: Keamogetswe Ramonaheng, et al.
Published: (2024-03-01)

Evaluation of the 177mLu-concentration in in-house produced 177Lu-radiopharmaceuticals and commercially available Lutathera®
by: Matthias Balzer, et al.
Published: (2023-11-01)

Lutetium-177-Prostate-Specific Membrane Antigen Radioligand Therapy: What Is the Value of Post-Therapeutic Imaging?
by: Jules Zhang-Yin
Published: (2024-07-01)

Impact of the dead-time correction method on quantitative 177Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy
by: Alessandro Desy, et al.
Published: (2022-08-01)

Selection and Use of Antioxidants-radioprotectors in the Composition of Therapeutic Radiopharmaceuticals (Review)
by: E. P. Pavlenko, et al.
Published: (2023-12-01)

Optimization of 177Lu-labelling of DOTA-TOC, PSMA-I&T and FAPI-46 for clinical application
by: Aylin Cankaya, et al.
Published: (2023-05-01)

Active bone marrow S-values for the low-energy electron emitter terbium-161 compared to S-values for lutetium-177 and yttrium-90
by: Jens Hemmingsson, et al.
Published: (2022-09-01)

Features and Practical Aspects of Radiochemical Purity Determination of Receptor-Specific Lu-177 Radiopharmaceuticals as Exemplified by [<sup>177</sup>Lu]Lu–PSMA-617
by: A. A. Larenkov, et al.
Published: (2022-12-01)

Determination of Critical Organ Doses with 177Lu Prostate-specific Membrane Antigen Dosimetry in Metastatic Prostate Cancer Treatment
by: Gulcihan Yilidir, et al.
Published: (2024-06-01)

Quantitative imaging for 177Lu-PSMA treatment response monitoring and dosimetry
by: Catherine Meyer, et al.
Published: (2023-12-01)

In Vivo Measurement and Characterization of a Novel Formulation of [177Lu]-DOTA-Octreotate
by: Dale Bailey, et al.
Published: (2016-01-01)

Inter-comparison of quantitative imaging of lutetium-177 (177Lu) in European hospitals
by: Jill Wevrett, et al.
Published: (2018-08-01)

Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation
by: Steffie M. B. Peters, et al.
Published: (2023-01-01)

The Recent Research Development of 177Lu Radiopharmaceuticals
by: YANG Yuchuan;KAN Wentao;YANG Xia;WEI Hongyuan;ZHUO Liangang;WANG Jing;LIAO Wei;ZHAO Peng;WANG Guanquan
Published: (2022-06-01)

Effect of <i>N</i>-Terminal Peptide Modifications on In Vitro and In Vivo Properties of <sup>177</sup>Lu-Labeled Peptide Analogs Targeting CCK2R
by: Anton Amadeus Hörmann, et al.
Published: (2023-02-01)

177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry
by: Ayman Abouzayed, et al.
Published: (2023-09-01)

Preliminary Study on Lutetium-177 and Gold Nanoparticles: Apoptosis and Radiation Enhancement in Hepatic Cancer Cell Line
by: Maria Anthi Kouri, et al.
Published: (2024-10-01)

Simultaneous Visualization of <sup>161</sup>Tb- and <sup>177</sup>Lu-Labeled Somatostatin Analogues Using Dual-Isotope SPECT Imaging
by: Francesca Borgna, et al.
Published: (2021-04-01)

Tumor dosimetry using 177Lu: influence of background activity, measurement method and reconstruction algorithm
by: Peter Frøhlich Staanum
Published: (2023-06-01)

Comparison of the dosimetry and cell survival effect of 177Lu and 161Tb somatostatin analog radiopharmaceuticals in cancer cell clusters and micrometastases
by: Laura De Nardo, et al.
Published: (2024-11-01)

No-Carrier-Added Lutetium-177 Separation Technology Status
by: LI Bo1, 2, 3, HU Yingjiang1, 2, 3, WU Jianrong1, 2, 3, WANG Lei1, 2, 3, CHEN Yunming1, 2, 3, ZHANG Jinsong1, 2, 3, LUO Ning1, 2, 3
Published: (2024-04-01)

Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177
by: Anton Amadeus Hörmann, et al.
Published: (2020-10-01)

Radioactivity distribution in the blood and urine of patients receiving systemic therapy with a <sup>177</sup>Lu radiopharmaceutical and local (intra-articular) therapy with a <sup>188</sup>Re radiopharmaceutical
by: E. D. Stepchenkova, et al.
Published: (2022-12-01)

Therapeutic Outcomes of 177Lu-PSMA Targeted Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Single-Center Study
by: Seyed Ali Mirshahvalad, et al.
Published: (2023-01-01)

Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy
by: Cyprine Neba Funeh, et al.
Published: (2023-04-01)

First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
by: Maryana Handula, et al.
Published: (2023-06-01)

Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177Lutetium
by: Kevin J. H. Allen, et al.
Published: (2019-07-01)

Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer
by: Rien Ritawidya, et al.
Published: (2023-11-01)

Impressive Response to TANDEM Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu/<sup>225</sup>AcDOTA-LM3 Somatostatin Receptor Antagonist in a Patient with Therapy-Refractory, Rapidly Progressive Neuroendocrine Neoplasm of the Pancreas
by: Elisabetta Perrone, et al.
Published: (2024-04-01)

Impact of dead time on quantitative 177Lu-SPECT (QSPECT) and kidney dosimetry during PRRT
by: Alessandro Desy, et al.
Published: (2020-05-01)

Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases
by: Hongmei Li, et al.
Published: (2024-03-01)

How much do 68Ga-, 177Lu- and 131I-based radiopharmaceuticals contribute to the global radiation exposure of nuclear medicine staff?
by: L. Struelens, et al.
Published: (2024-11-01)

Electrochemical separation and purification of no-carrier-added 177Lu for radiopharmaceutical preparation: Translation from bench to bed
by: Sourav Patra, et al.
Published: (2023-05-01)

Developments in 177Lu-based radiopharmaceutical therapy and dosimetry
by: Siju C. George, et al.
Published: (2023-07-01)

The Establishment of the Enterprise Internal Control Quality Standard for No-carrier-added Lutetium ［177Lu］ Chloride Solution
by: LUO Tianwei;CHEN Mengyi;WANG Chunlin;SUN Xiangmin;YANG Liu;WANG Xiaoming;KONG Xiaohui;WU Fuhai;HUANG Xiaoyan;QIU Yanli;ZHANG Yun;LI Hongyu
Published: (2023-02-01)

Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu]Lu-DOTATATE
by: Javian C. Malcolm, et al.
Published: (2022-03-01)

Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT
by: Dagmar Grob, et al.
Published: (2024-04-01)

Production and Evaluation of Lutetium-177 Maltolate as a Possible Therapeutic Agent
by: A Hakimi, et al.
Published: (2012-08-01)

Simultaneous Determination of Two Stabilizers Content in Lutetium[177Lu] Oxodotreotide Injection by High-Performance Liquid Chromatography
by: Yong WANG, et al.
Published: (2025-02-01)

Corrigendum: Developments in 177Lu-based radiopharmaceutical therapy and dosimetry
by: Siju C. George, et al.
Published: (2024-04-01)